Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
Noise can play an important role in the initiation and progression of ischemic heart disease. Researchers from the Department of Cardiology at the University Medical Center Mainz have found that noise exposure...
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
Cancer death rates higher for children in neighborhoods with persistent poverty, study finds
2.
Treatment of Smoldering Myeloma Cuts Progression Rate in Half
3.
Specific suicidal patterns mark the highest risk.
4.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
5.
A computer-aided diagnostic system for improved detection of breast cancer.
1.
The Science Behind Imatinib: How It Targets Cancer Cells
2.
Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC
3.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
4.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
5.
Exploring the Role of Fecal Leukocytes in Intestinal Health
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
Navigating the Complexities of Ph Negative ALL - Part XVI
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge